Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZSP1602 in Advanced Solid Tumors
NCT03734913Phase 1Unknown
- Sponsor
- Zhongsheng Pharma
- Start
- Jan 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ZSP1602 in basal cell carcinoma (BCC), medulloblastoma, adenocarcinoma of the esophagogastric junction (AEG) and 4 more (3 arms), sponsored by Zhongsheng Pharma. Primary endpoints: Dose-limiting Toxicity at Day 32 and Maximum Tolerated Dose at Day 32. Status: unknown.
02
Drugs
ZSP1602
03
Conditions
basal cell carcinoma (BCC)medulloblastomaadenocarcinoma of the esophagogastric junction (AEG)small cell lung cancer (SCLC)Neuroendocrine neoplasm (NEN)
Beyond the preview
Go deeper on NCT03734913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03734913.